Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

ClinicalTrials.gov ID: NCT02696148

Public ClinicalTrials.gov record NCT02696148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in the United States of America. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of liraglutide in obese children aged 7 to 11 years

Study identification

NCT ID
NCT02696148
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
24 participants

Conditions and interventions

Eligibility (public fields only)

Age range
7 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 13, 2016
Primary completion
Apr 12, 2017
Completion
Apr 12, 2017
Last update posted
Mar 17, 2019

2016 – 2017

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site New Haven Connecticut 06520
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Pensacola Florida 32504
Novo Nordisk Investigational Site Atlanta Georgia 30331
Novo Nordisk Investigational Site Buffalo New York 14203
Novo Nordisk Investigational Site Mineola New York 11501
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224
Novo Nordisk Investigational Site Memphis Tennessee 38119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Obesity trials

Other public records listing Obesity. Sorted by last update posted; newest first. Not a recommendation.

All Obesity trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02696148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 17, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02696148 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →